Methylphenidate for attention deficit hyperactivity disorder and drug relapse in criminal offenders with substance dependence: a 24-week randomized placebo-controlled trial
Article first published online: 1 DEC 2013
© 2013 Society for the Study of Addiction
How to Cite
Konstenius, M., Jayaram-Lindström, N., Guterstam, J., Beck, O., Philips, B. and Franck, J. (2013), Methylphenidate for attention deficit hyperactivity disorder and drug relapse in criminal offenders with substance dependence: a 24-week randomized placebo-controlled trial. Addiction. doi: 10.1111/add.12369
- Article first published online: 1 DEC 2013
- Accepted manuscript online: 4 OCT 2013 01:45AM EST
- Manuscript Accepted: 25 SEP 2013
- Manuscript Revised: 26 APR 2013
- Manuscript Received: 9 FEB 2013
- Swedish National Board of Health and Welfare
- Swedish Research Council
- Stockholm County Council
- substance use
To test the efficacy and safety of osmotic release oral system (OROS) methylphenidate (MPH) in doses up to 180 mg/day to treat attention deficit hyperactivity disorder (ADHD) and prevent any drug relapse in individuals with a co-diagnosis of ADHD and amphetamine dependence.
Randomized placebo-controlled 24-week double-blind trial with parallel groups design.
Participants were recruited from medium security prisons in Sweden. The medication started within 2 weeks before release from prison and continued in out-patient care with twice-weekly visits, including once-weekly cognitive behavioural therapy.
Fifty-four men with a mean age of 42 years, currently incarcerated, meeting DSM-IV criteria for ADHD and amphetamine dependence.
Change in self-reported ADHD symptoms, relapse to any drug use (amphetamine and other drugs) measured by urine toxicology, retention to treatment, craving and time to relapse.
The MPH-treated group reduced their ADHD symptoms during the trial (P = 0.011) and had a significantly higher proportion of drug-negative urines compared with the placebo group (P = 0.047), including more amphetamine-negative urines (P = 0.019) and better retention to treatment (P = 0.032).
Methylphenidate treatment reduces attention deficit hyperactivity disorder symptoms and the risk for relapse to substance use in criminal offenders with attention deficit hyperactivity disorder and substance dependence.